Research map: Tecovirimat treatment of clade II mpox: a virological analysis of a randomised, double-blind, phase 3 trial

Back to the article

Papers in this map

  1. An amplicon-based sequencing framework for accurately measuring intrahost virus diversity using PrimalSeq and iVar · Nathan D. Grubaugh · 2019 · 1191 citations · Cited by this paper
  2. VRON-0200 alone and in combination with investigational antivirals for participants with chronic hepatitis B virus infection receiving stable nucleos(t)ide therapy: a phase 1b, randomised, open-label, multicentre trial · 2026 · Related
  3. Species-specific differentiation of variola, monkeypox, and varicella-zoster viruses by multiplex real-time PCR assay · Rinat А. Maksyutov · 2016 · 135 citations · Cited by this paper
  4. ESCMID Global Congress 2026 · 2026 · Related
  5. Tecovirimat Resistance in Mpox Patients, United States, 2022–2023 · Todd G. Smith · 2023 · 129 citations · Cited by this paper
  6. Context-dependent and ecological drivers of neonatal invasive Escherichia coli population dynamics—Authors’ reply · 2026 · Related
  7. Tecovirimat for Clade I MPXV Infection in the Democratic Republic of Congo · The PALM007 Writing Group · 2025 · 121 citations · Cited by this paper
  8. Interchangeability of blood culture bottles and automats for blood culture systems: an in-vitro performance evaluation · 2026 · Related
  9. The development and approval of tecoviromat (TPOXX®), the first antiviral against smallpox · Michael J. Merchlinsky · 2019 · 113 citations · Cited by this paper
  10. The hantavirus question we are not asking · 2026 · Related
  11. Treatment with the Smallpox Antiviral Tecovirimat (ST-246) Alone or in Combination with ACAM2000 Vaccination Is Effective as a Postsymptomatic Therapy for Monkeypox Virus Infection · Aklile Berhanu · 2015 · 111 citations · Cited by this paper
  12. Evaluation of the effectiveness of artemether–lumefantrine and artesunate–pyronaridine each combined with single low-dose primaquine in adults with Plasmodium falciparum infection in Ethiopia: a phase 2/3, observer-masked, randomised, parallel-group trial · 2026 · Related
  13. Effects of Treatment Delay on Efficacy of Tecovirimat Following Lethal Aerosol Monkeypox Virus Challenge in Cynomolgus Macaques · Andrew T. Russo · 2018 · 89 citations · Cited by this paper
  14. Genotype-based antimicrobial resistance tests need a new regulatory framework · 2026 · Related
  15. Evaluation and clinical validation of monkeypox (mpox) virus real-time PCR assays · Margaret G. Mills · 2022 · 67 citations · Cited by this paper
  16. Saliva versus lesion swabs for PCR diagnosis of acute-phase clade Ib mpox in Uganda: a prospective matched hospital cohort study · 2026 · Related
  17. Structural insights into tecovirimat antiviral activity and poxvirus resistance · Riccardo Vernuccio · 2025 · 53 citations · Cited by this paper
  18. Strengthening pre-spillover surveillance: the missing link in Ebola preparedness · 2026 · Related
  19. Assessing a drug for an eradicated human disease: US Food and Drug Administration review of tecovirimat for the treatment of smallpox · Kirk M. Chan‐Tack · 2019 · 45 citations · Cited by this paper
  20. Andes virus induces a chemokine-dominant endothelial and stromal activation pattern that promotes immune-cell recruitment · 2026 · Related
  21. Tecovirimat Use under Expanded Access to Treat Mpox in the United States, 2022–2023 · Patricia A. Yu · 2024 · 42 citations · Cited by this paper
  22. ORF-Interrupting Mutations in Monkeypox Virus Genomes from Washington and Ohio, 2022 · Jaydee Sereewit · 2022 · 38 citations · Cited by this paper
  23. Tecovirimat for the Treatment of Mpox · Jason E Zucker · 2026 · 33 citations · Cited by this paper
  24. Notes from the Field: Mpox Cluster Caused by Tecovirimat-Resistant Monkeypox Virus — Five States, October 2023–February 2024 · Crystal M. Gigante · 2024 · 31 citations · Cited by this paper
  25. Overview of the regulatory approval of tecovirimat intravenous formulation for treatment of smallpox: potential impact on smallpox outbreak response capabilities, and future tecovirimat development potential · Andrew T. Russo · 2023 · 18 citations · Cited by this paper
  26. Early administration of tecovirimat shortens the time to mpox clearance in a model of human infection · Bach Tran Nguyen · 2023 · 16 citations · Cited by this paper
  27. Prolonged viral shedding in an immunocompromised Korean patient infected with hMPXV, sub‐lineage B.1.3, with acquired drug resistant mutations during tecovirimat treatment · Minji Lee · 2024 · 14 citations · Cited by this paper
  28. Genomic Analysis of Early Monkeypox Virus Outbreak Strains, Washington, USA · Pavitra Roychoudhury · 2023 · 13 citations · Cited by this paper
  29. Analyzing Longitudinally Collected Viral Load Measurements in Youth With Perinatally Acquired HIV Infection: Problems and Possible Remedies · Sean S. Brummel · 2022 · 3 citations · Cited by this paper

Source: OpenAlex (CC0)